Details
Stereochemistry | RACEMIC |
Molecular Formula | C3H2ClF5O |
Molecular Weight | 184.492 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)OC(Cl)C(F)(F)F
InChI
InChIKey=PIWKPBJCKXDKJR-UHFFFAOYSA-N
InChI=1S/C3H2ClF5O/c4-1(3(7,8)9)10-2(5)6/h1-2H
Molecular Formula | C3H2ClF5O |
Molecular Weight | 184.492 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Isoflurane (1-chloro-2, 2,2-trifluoroethyl difluoromethyl ether) a nonflammable liquid administered by vaporizing, is a general inhalation anesthetic drug. Isoflurane is a clear, colorless, stable liquid containing no additives or chemical stabilizers. Similar to many general anesthetics, the exact mechanism of the action has not been clearly delineated. Isoflurane reduces pain sensitivity (analgesia) and relaxes muscles. Isoflurane likely potentiates GABA-A and glycine receptor activity, which decreases motor function, inhibits receptor activity in the NMDA glutamate receptor subtypes and binds to glutamate receptors. Isoflurane is always administered in conjunction with air and/or pure oxygen. Often nitrous oxide is also used. Although its physical properties imply that anesthesia can be induced more rapidly than with halothane, its pungency can irritate the respiratory system, negating this theoretical advantage conferred by its physical properties. It is usually used to maintain a state of general anesthesia that has been induced with another drug, such as thiopentone or propofol.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16973644 |
|||
Target ID: CHEMBL3392921 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16973644 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FORANE Approved UseINDICATIONS & USAGE Isoflurane may be used for induction and maintenance of general anesthesia. Adequate data have not been developed to establish its application in obstetrical anesthesia. Launch Date1979 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
800 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23015620/ |
180 mg/kg single, intravenous dose: 180 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ISOFLURANE plasma | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.765 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23015620/ |
180 mg/kg single, intravenous dose: 180 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ISOFLURANE plasma | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.01 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23015620/ |
180 mg/kg single, intravenous dose: 180 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
ISOFLURANE plasma | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1382.4 % * h multiple, respiratory Highest studied dose Dose: 1382.4 % * h Route: respiratory Route: multiple Dose: 1382.4 % * h Sources: |
unhealthy, 25 years n = 1 Health Status: unhealthy Age Group: 25 years Sex: M Population Size: 1 Sources: |
|
1975.2 % * h multiple, respiratory Highest studied dose Dose: 1975.2 % * h Route: respiratory Route: multiple Dose: 1975.2 % * h Sources: |
unhealthy, 4 years n = 1 Health Status: unhealthy Age Group: 4 years Sex: F Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/7720526/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/7720526/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/7720526/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/7720526/ |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/7720526/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of chronic exposure to anaesthetic gases on some immune parameters. | 2001 Apr 10 |
|
Increase in rat plasma antioxidant activity after E. coli lipopolysaccharide administration. | 2001 Feb |
|
An experimental study on the relationship of intra-abdominal pressure and renal ischemia. | 2001 Feb |
|
High concentrations of isoflurane do not block the sympathetic nervous system activation from desflurane. | 2001 Feb |
|
Absence of direct antioxidant effects from volatile anesthetics in primary mixed neuronal-glial cultures. | 2001 Feb |
|
Cardiovascular effects of sevoflurane, isoflurane, halothane, and fentanyl-midazolam in children with congenital heart disease: an echocardiographic study of myocardial contractility and hemodynamics. | 2001 Feb |
|
Clinical evaluation of the Mapleson theoretical ideal fresh gas flow sequence at the start of low-flow anaesthesia with isoflurane, sevoflurane and desflurane. | 2001 Feb |
|
Smoking status and body size increase carbon monoxide concentrations in the breathing circuit during low-flow anesthesia. | 2001 Feb |
|
Propofol action in both spinal cord and brain blunts electroencephalographic responses to noxious stimulation in goats. | 2001 Feb 1 |
|
Comparative analysis of costs of total intravenous anaesthesia with propofol and remifentanil vs. balanced anaesthesia with isoflurane and fentanyl. | 2001 Jan |
|
[Anesthesia for a patient with cardiac sarcoidosis]. | 2001 Jan |
|
A follow-up study on occupational exposure to inhaled anaesthetics in Eastern European surgeons and circulating nurses. | 2001 Jan |
|
Effects of isoflurane on nitric oxide metabolism and oxidant status of guinea pig myocardium. | 2001 Jan |
|
Effect of hyperoxia, hypercapnia, and hypoxia on cerebral interstitial oxygen tension and cerebral blood flow. | 2001 Jan |
|
The effects of anesthetics on cortical spreading depression elicitation and c-fos expression in rats. | 2001 Jan |
|
Effects of neuroprotective cocktails on hippocampal neuron death in an in vitro model of cerebral ischemia. | 2001 Jan |
|
Intracranial electroencephalographic changes in deep anesthesia. | 2001 Jan |
|
Cerebral hemodynamic response to the introduction of desflurane: a comparison with sevoflurane. | 2001 Jan |
|
Neither GABA(A) nor strychnine-sensitive glycine receptors are the sole mediators of MAC for isoflurane. | 2001 Jan |
|
Fast-track office-based anesthesia: a comparison of propofol versus desflurane with antiemetic prophylaxis in spontaneously breathing patients. | 2001 Jan |
|
Effect of isoflurane versus nicardipine on blood flow of lumbar paraspinal muscles during controlled hypotension for spinal surgery. | 2001 Jan 1 |
|
The effect of epidural anesthesia on respiratory distress induced by airway occlusion in isoflurane-anesthetized cats. | 2001 Mar |
|
The effect of the preemptive use of the NMDA receptor antagonist dextromethorphan on postoperative analgesic requirements. | 2001 Mar |
|
The effects of low-flow sevoflurane and isoflurane anesthesia on renal function in patients with stable moderate renal insufficiency. | 2001 Mar |
|
Evidence for a common binding cavity for three general anesthetics within the GABAA receptor. | 2001 Mar 15 |
|
Genomic and functional characteristics of novel human pancreatic 2P domain K(+) channels. | 2001 Mar 23 |
|
The efficacy and resource utilization of remifentanil and fentanyl in fast-track coronary artery bypass graft surgery: a prospective randomized, double-blinded controlled, multi-center trial. | 2001 May |
|
Clonidine decreases intraoperative bleeding in middle ear microsurgery. | 2001 May |
Patents
Sample Use Guides
Inspired concentrations of 1.5 to 3.0% isoflurane usually produce surgical anesthesia in 7 to 10 minutes.
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16973644
The effects of isoflurane and enflurane on spontaneous action potential firing were investigated by extracellular voltage recordings from ventral horn interneurones in cultured spinal cord tissue slices obtained from embryonic rats. Spinal cord slices were continuously perfused with an artificial cerebrospinal fluid (ACSF). Test solutions including isoflurane (0.32 mM) was prepared by dissolving the liquid form in ACSF equilibrated with 95% oxygen and 5% carbon dioxide. Anaesthetics were administered via bath perfusion
using gas-tight syringe pumps. The flow rate was approximately 1 ml min-1. To ensure steady-state conditions, recordings during anaesthetic treatment were carried out 10–15 min after starting the perfusate change.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:24:53 GMT 2023
by
admin
on
Fri Dec 15 16:24:53 GMT 2023
|
Record UNII |
CYS9AKD70P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175681
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
1.1.1
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
||
|
NCI_THESAURUS |
C245
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
||
|
WHO-ATC |
N01AB06
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
||
|
LIVERTOX |
NBK548501
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
||
|
WHO-VATC |
QN01AB06
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
||
|
NDF-RT |
N0000175975
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m6491
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
26675-46-7
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
Isoflurane
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
6026
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | RxNorm | ||
|
6015
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
DB00753
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
C65978
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
1493
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
CYS9AKD70P
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
3286
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
DTXSID3020752
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
8057
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
2505
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
ISOFLURANE
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
CYS9AKD70P
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
D007530
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
3763
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
SUB08319MIG
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL1256
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
1349003
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
100000091651
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY | |||
|
247-897-7
Created by
admin on Fri Dec 15 16:24:54 GMT 2023 , Edited by admin on Fri Dec 15 16:24:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> AGONIST |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (GC)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|